Extended Reduced Dose Apixaban for Cancer-Associated VTE

The study on extended reduced dose apixaban focuses on patients with cancer-associated venous thromboembolism and aims to determine if this treatment approach improves outcomes regarding recurrent thromboembolic events while reducing bleeding risks. Conducted as a double-blind, randomized control trial, the research included approximately 1,700 patients with active cancer who had previously completed at least six months of anticoagulation treatment. The results indicated that the reduced dose group experienced a recurrent or fatal VTE rate of 2.1% compared to 2.8% in the full dose group, suggesting that the lower dose was non-inferior. Furthermore, the bleeding risk was lower in the reduced dose group, pointing to a potentially significant shift in treatment protocols for these high-risk patients.